Hemostemix Inc. (CVE:HEM – Get Free Report) shares hit a new 52-week low on Thursday . The stock traded as low as C$0.04 and last traded at C$0.05, with a volume of 10500 shares trading hands. The stock had previously closed at C$0.05.
Hemostemix Trading Down 11.1 %
The company has a market cap of C$3.48 million, a price-to-earnings ratio of -1.33 and a beta of 0.62. The business’s 50 day moving average price is C$0.05 and its 200-day moving average price is C$0.06.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Read More
- Five stocks we like better than Hemostemix
- What Is WallStreetBets and What Stocks Are They Targeting?
- Why Call Options Volume for These 2 Stocks Spiked Together
- Conference Calls and Individual Investors
- MarketBeat Week in Review – 7/22 – 7/26
- What is the Shanghai Stock Exchange Composite Index?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.